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Aims:  The  aim  of  this  study  was  to evaluate  the  abuse  potential  of dasotraline,  a novel  dopamine  and
norepinephrine  reuptake  inhibitor  with  slow  absorption  (tmax, 10–12  h)  and  elimination  (t1/2 =  47–77 h)
that  is in  development  for  the  treatment  of  attention  deﬁcit  hyperactivity  disorder  (ADHD).
Methods:  Recreational  stimulant  users  (N =  48)  who  had  speciﬁc  experience  with  cocaine,  and  who  were
able to distinguish  methylphenidate  (60  mg)  versus placebo  in  a qualiﬁcation  session,  were  randomized,
in  a  6-period,  double-blind,  crossover  design,  to receive  single  doses  of  dasotraline  8 mg,  16 mg,  and  36 mg,
methylphenidate  (MPH)  40 mg and 80 mg, and  placebo.  The  primary  endpoint  was  the Drug Liking Visual
Analog  Scale  (VAS)  score  at the  time  of  peak  effect  (Emax).
Results:  There were  no  signiﬁcant  differences  between  the  3 doses  of  dasotraline  and  placebo  on the  drug
liking  VAS  at  Emax, and  on most secondary  endpoints.  Both  doses  of  MPH  had signiﬁcantly  higher  VAS-
drug  liking  scores  at  Emax relative  to both  placebo  (P < 0.001  for  all  comparisons)  and  dasotraline  8 mgmphetamines (P  <  0.001),  16  mg (P < 0.001)  and  36  mg  (P < 0.01).  The  increase  in  heart  rate  for MPH  and  dasotraline
36 mg  showed  a time-course  that closely  matched  subject-rated  measures  such  as  Any Effects  VAS.
Conclusions:  In  this  study,  dasotraline  was  found  to  have low  potential  for abuse,  which  may  be,  in part,
related  to its  established  pharmacokinetics  (PK)  proﬁle,  which  is characterized  by slow  absorption  and
gradual  elimination.
rs.  Pu©  2015  The  Autho
. Introduction
Drugs that increase dopamine levels may  be associated with
timulant effects and abuse (e.g., cocaine and amphetamine),
hereas drugs that increase 5-HT and/or NE levels are not gen-
rally associated with recreational abuse (e.g., selective serotonin
euptake inhibitors, atomoxetine). Several of the most widely pre-
cribed treatments for ADHD (e.g., methylphenidate, amphetamine
reparations) increase dopamine levels, and are typically asso-
iated with stimulant effects, increased risk of abuse (Wilens
t al., 2008), and enhanced vulnerability to abuse of other drugs
Mannuzza et al., 2008; Dalsgaard et al., 2014).Dasotraline [(1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetra-
ydronaphthalen-1-amine] is a potent inhibitor of human
A transporters (DAT; dopamine uptake IC50 3 nM)  and NE
∗ Corresponding author at: Sunovion Pharmaceuticals Inc., 84 Waterford Drive,
arlborough, MA  01752, USA. Tel.: +1 5087874356.
E-mail address: Kenneth.Koblan@Sunovion.com (K.S. Koblan).
1 Currently at Altreos Research Partners, Toronto, ON, Canada.
ttp://dx.doi.org/10.1016/j.drugalcdep.2015.10.029
376-8716/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
transporters (NET; norepinephrine uptake IC50 4 nM), and a
weaker inhibitor of human serotonin transporters (SERT; sero-
tonin uptake IC50 15 nM;  Sunovion, data-on-ﬁle, 2014). In humans,
dasotraline has a time to maximum plasma concentration (tmax)
of 10–12 h, a terminal elimination half-life (t1/2) of 47–77 h, and
achieves steady state plasma concentration after 2 weeks of daily
dosing (Koblan et al., 2015; Hopkins et al., 2015). Among drugs
with effects on dopamine neurotransmission, drugs with a slow
onset of effect typically have reduced abuse potential (Busto and
Sellers, 1986; Farré and Camí, 1991; Volkow et al., 1995; Volkow
and Swanson, 2003; Swanson and Volkow, 2003). In addition,
there is evidence that an increased half-life reduces the rewarding
effects and lowers abuse liability due to sustained elevations
in drug concentrations resulting in sustained inhibition of DA
transporters (Swanson and Volkow, 2003; Schoedel et al., 2010).
Dasotraline is being developed to evaluate its use in treating
the symptoms of attention-deﬁcit/hyperactivity disorder (ADHD;
American Psychiatric Association, 2013). A 4-week, ﬁxed-dose,
placebo-controlled trial supported dasotraline as an efﬁcacious
treatment option for adults with ADHD (Koblan et al., 2015). Thus,
the pharmacokinetic and pharmacodynamic characteristics of
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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asotraline suggest that its therapeutic effects in the treatment of
DHD, with sustained inhibition of DA and NE reuptake, may  be
ssociated with lower abuse potential than methylphenidate.
The primary aim of the current study was to evaluate the abuse
otential of dasotraline compared to placebo and methylphenidate
n recreational stimulant users. Peak Drug Liking VAS (“at this
oment”) was selected as the primary endpoint since it is the
tandard measure of abuse in human abuse liability studies. (Food
nd Drug Administration, 2010, 2013).
. Methods
.1. Design and subjects
This was a randomized, double-blind, double-dummy, 6-way
rossover study in healthy recreational stimulant users in which
he abuse potential of single doses of dasotraline (8 mg,  16 mg,  and
6 mg)  were compared to placebo and methylphenidate (40 mg  and
0 mg;  positive controls).
The study was conducted at a single clinical research unit located
n Toronto, Ontario, Canada (INC Research Toronto, Inc.), was
pproved by the local IRB, and was conducted in accordance with
CH GCP guidelines and with the Declaration of Helsinki. All subjects
eviewed and signed an informed consent document explaining
tudy procedures and potential risks. Subjects were compensated
or their participation in the study according to local guidelines.
Healthy recreational CNS stimulant users, age 18–55 inclu-
ive, were eligible for enrollment if they reported a history of
10 lifetime experiences with CNS stimulants (e.g., amphetamines,
ocaine, methylphenidate), and use of a CNS stimulant within 12
eeks prior to Screening, and use of cocaine within 12 months
rior to Screening. Reasons for exclusion included: an active med-
cal condition, including clinically signiﬁcant neurological illness,
r psychiatric illness (as assessed by the Symptom Checklist-
0-Revised [SCL-90-R]); any clinically signiﬁcant abnormality on
hysical examination, laboratory testing, or ECG; subjects currently
ith pending legal charges or on probation; subjects meeting DSM-
V-TR criteria (American Psychiatric Association, 2000) for drug or
lcohol dependence (excluding nicotine and caffeine) or who had
ver been in a substance rehabilitation program.
.2. Study drug
Three doses of dasotraline were tested (8 mg,  16 mg,  36 mg)  to
llow examination of the dose-response curve ranging from a high
herapeutic dose (8 mg)  to a supra-therapeutic dose (36 mg)  con-
istent with standard guidelines for abuse liability studies (Balster
nd Bigelow, 2003; Food Drug Administration, 2013; Grifﬁths et al.,
003; McColl and Sellers, 2006). The 40 mg  and 80 mg  doses of
ethylphenidate were selected based on previous studies (Kollins
t al., 2001; Parasrampuria et al., 2007a,b) identifying these as
oses that produced signiﬁcant positive psychostimulant effects
hile minimizing potentially aversive effects, such as dizziness or
ausea, that are associated with doses >80 mg  that can increase rat-
ngs of negative effects and potentially confound the assessment of
ewarding effects such as ratings of Drug Liking.
To ensure double-dummy, double-blind administration, the
apsules received at each treatment visit were identical. Each
ose consisted of 20 capsules: 18 capsules of either dasotraline
r matching placebo, and 2 capsules of either methylphenidate or
atching placebo. Methylphenidate was supplied as 20 mg  tablets
f immediate-release Ritalin® that were encapsulated on site into
Ael gel capsules; matching placebo was supplied as lactose 100 mg
lacebo tablets, also encapsulated into AAel gel capsules. Dasotra-
ine (and matching placebo) was supplied as 2 mg  Size #1 Swedishependence 159 (2016) 26–34 27
orange opaque hard gelatin capsules. Based on the long t1/2 of daso-
traline (47–77 h), the minimum washout period between doses in
the treatment phase was  21 days.
2.3. Study phases
2.3.1. Qualiﬁcation phase. To conﬁrm eligibility for the treatment
phase of the study, subjects ﬁrst completed a randomized, 4-day,
double-blind, crossover qualiﬁcation phase, in which they received
single oral doses of immediate-release methylphenidate (60 mg)
or matching placebo, separated by a 24 h washout. A subject was
eligible for the treatment phase only if the following eligibility crite-
ria were met  in the qualiﬁcation phase: (1) their peak score on
the Drug Liking Visual Analog Scale (VAS) was 10-points higher
in response to methylphenidate versus placebo response; placebo
response was  required to be in the range of 45 to 55 on the Drug
Liking VAS (so that subjects neither endorsed liking nor disliking
of placebo); and (2) safety data at the 60 mg  dose methylphenidate
suggested that the subject would be able to tolerate the 80 mg  dose
of methylphenidate in the treatment phase.
2.3.2. Treatment phase. Subjects who met  eligibility criteria based
on the results of the qualiﬁcation phase were randomized to single
oral doses in 1 of 6 treatment sequences based on a computer-
generated randomization schedule, according to a 6 × 6 Williams
square design (Williams, 1949). Subjects received their assigned
dose, in the order speciﬁed, using a double-dummy procedure.
Each treatment visit was  5 days to collect PK and pharmacody-
namic measures up to 72 h postdose, with a 21-day washout period
between each treatment visit. Subjects returned for a safety follow-
up visit within 14 days after the last administration of study drug.
2.4. Pharmacodynamic measurements
Subjects underwent initial training and practice sessions. Visual
analog scale (VAS) measures were scored on a 0–100 scale (Food
Drug Administration, 2010, 2013). The VAS for Drug Liking (at
this moment), Overall Drug Liking, and Alertness/Drowsiness (“my
mental state is”) used bipolar VAS scoring, with 50 as a neutral
score, and 0 = strong disliking (or drowsiness), and 100 = strong lik-
ing (or alertness). The VAS for Good Effects (“I can feel good drug
effects”), Bad Effects (“I can feel bad drug effects”), Any Effects
(“I can feel any drug effect”), Take Drug Again (“I would take this
drug again”), and Drug Similarity, used unipolar VAS scoring, with
0 = deﬁnitely not, and 100 = deﬁnitely yes. Drug Similarity VASs
(“how similar is the drug you most recently received to [drug
name]?”) provided an estimate of similarity between dasotraline
and drugs of other classes with which the subject was  familiar,
including placebo. Subjects were asked about cocaine (including
crack), caffeine, ecstasy (MDMA), D-amphetamine or metham-
phetamine, phencyclidine (PCP), codeine or morphine, heroin,
LSD, nicotine, pseudoephedrine, THC, benzodiazepines, ketamine,
and about their “overall familiarity” with each drug. The 49-item
Addiction Research Center Inventory (ARCI) was  also administered
(Martin et al., 1971). Four ARCI scales were used in the current
study: MBG  (euphoria), A and BG (stimulant effects), and LSD
(dysphoria). An assessment of the Subjective Drug Value (SDV)
was performed based on a procedure adapted from Grifﬁths et al.
(2003); the permissible payment range was $0.25 to $50. Measures
were administered and data were captured electronically using
computerized proprietary software (Scheduled Measurement Sys-
tem, INC Research Toronto, Inc.).The timing of assessments were as follows: VAS scales and ARCI
measures were performed pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8,
9, 10, 10.5, 11, 11.5, 12, 13, 14, 24, 36, 48, and 72 h post-dose (and
then repeated at the same intervals on Days 2 and 3; Drug Liking
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AS/ARCI were also performed at 0.5 and 1.5 h post-dose); Subjec-
ive Drug Value, Overall Drug Liking VAS, and Take Drug Again VAS
t 24, 48, and 72 h post-dose; and adverse events and vital signs
ere recorded at pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 9, 10, 11,
2, 13, 14, 24, 36, 48, and 72 hours post-dose. Continuous cardiac
onitoring (telemetry and pulse oximetry) was performed from
re-dose until at least 12 h post-dose.
.5. Pharmacokinetic assessments
Blood samples were obtained pre-dose and 1, 2, 3, 6, 8, 10, 12, 14,
4, 36, 48, and 72 h post-dose (to maintain the double-blind, sam-
les were obtained after all study treatments, including placebo).
he plasma PK parameters included time to maximum observed
lasma concentration (tmax), maximum observed plasma concen-
ration (Cmax), and area under the plasma concentration-time curve
rom zero to the last measurable concentration (AUC0-last). Plasma
oncentrations for dasotraline were determined using a validated
ioanalytical method via HPLC with MS/MS  detection. Inter-assay
oefﬁcient of variation ranged from 1.97 to 2.49%; lower limit of
uantitation (LLOQ) was 10 pg/mL.
.6. Safety assessments
Safety and tolerability were assessed by vital signs, physical
xamination, clinical laboratory tests including breath alcohol test
nd urine drug screens at each study visit, continuous cardiac
elemetry, and monitoring of adverse events. Treatment-emergent
uicidal ideation was monitored using the Columbia Suicide Sever-
ty Rating Scale (C-SSRS; Posner et al., 2011).
.7. Statistical methods
The primary pharmacodynamic endpoint in the study was peak
core (Emax) on Drug Liking VAS. Pharmacodynamic endpoints
Emax, Emin, time averaged under the effect curve [TA AUE]) were
nalyzed using a mixed-effects model for a crossover study. The
odel included treatment, period, sequence, and ﬁrst order car-
yover effect as ﬁxed effects, baseline (pre-dose) measurement as
ovariate where applicable, and subject nested within treatment
equence as a random effect. If the carryover effect was found to
e non-signiﬁcant at the 25% level, then the term was  dropped
rom the analysis model. The residuals from the mixed-effect model
ere investigated for normality using the Shapiro–Wilk W-test.
arameters (Take Drug Again and Any Effects VAS Emax) that did
ot meet a normal distribution criterion (P ≥ 0.05) were analyzed
on-parametrically. For non-parametric analyses, overall treat-
ent effect was assessed using Friedman’s test; pairwise treatment
omparisons were assessed using the Wilcoxon signed-rank test on
he within-subject differences. The Benjamini and Hochberg pro-
edure was used to control for Type I error arising from multiple
reatment comparisons, only for the primary endpoint (Benjamini
nd Hochberg, 1995).
PK parameters for dasotraline (Cmax, tmax, and AUC0-last) were
alculated using non-compartmental analysis, and were summa-
ized using descriptive statistics.
. Results
.1. Qualiﬁcation phase
In the qualiﬁcation phase, 105 subjects entered a randomized,
-day, double-blind, crossover qualiﬁcation phase in which they
eceived single oral doses of immediate-release methylphenidate
60 mg)  or matching placebo. Subjects met  qualiﬁcation phase eli-
ibility criteria if the Drug Liking VAS value for methylphenidateependence 159 (2016) 26–34
at Emax was  ≥65, and the value following placebo administration
was 45–55, inclusive. A total of 52 subjects met  these criteria, with
a mean Emax Drug Liking VAS for methylphenidate of 87.3 (range,
65.0 to 100.0), and a mean Emax Drug Liking VAS for placebo of 50.8
(range, 50.0 to 55.0).
3.2. Subjects and disposition
Of the total of 52 subjects who  met  qualiﬁcation phase crite-
ria, 48 subjects entered the treatment phase, and 35 subjects
completed all treatment visits and, accordingly, comprise the
pharmacodynamic analysis population. Of the 13 subjects who
discontinued prematurely, the most common reason for discon-
tinuation was  withdrawal of consent (n = 4), followed by protocol
violation, adverse event (n = 2 each), and miscellaneous other rea-
sons (n = 1 each). Three subjects were discontinued during the
treatment phase due to positive urine drug screens (for cocaine,
THC).
The PK analysis population consisted of 45 subjects for whom
sufﬁcient plasma observations were available. For the pharmaco-
dynamic population, 74.3% were male, with a mean (SD) age of
34.2 (9.7) years; all but 2 subjects were white. Mean (SD) BMI for
the PK and pharmacodynamic populations were 24.8 (2.99) and
24.4 (2.89), respectively. All subjects reported stimulant use, 85.7%
reported previous experience with cannabinoids, 48.6% with opi-
oids, 34.3% with hallucinogens, 20.0% with CNS depressants, and
11.4% with dissociative anesthetics.
3.3. Pharmacodynamic results
3.3.1. Validity of the study and study measures. Signiﬁcantly greater
peak effects were observed for both doses of methylphenidate
compared to placebo on all positive, stimulant, and overall pharma-
codynamic measures (Tables 1 and 2), thus conﬁrming the validity
of both the study population and the study measures as an assay
for potential stimulant abuse liability. In addition, methylphenidate
was strongly identiﬁed as a stimulant (e.g., d-amphetamine,
methamphetamine, or cocaine) and strongly identiﬁed as not
placebo on the Drug Similarity VAS (Fig. 1).
3.3.2. Peak pharmacodynamic effects (Emax). The peak effects of all 3
doses of dasotraline were not different from placebo on the primary
endpoint (Drug Liking VAS at Emax), and on the secondary endpoint,
Overall Drug Liking VAS at Emax (Table 1).
For the 8 mg  and 16 mg  doses of dasotraline, peak effects were
not different from placebo on the full range of secondary end-
points, including Take Drug Again VAS, measures of stimulant
effect (ARCI MBG, BG, and Amphetamine scales; Table 1), and other
standard pharmacodynamic measures including Subjective Drug
Value (SDV), High VAS, Good Effects VAS, Alertness VAS, Energized
VAS, and Any Effects VAS and the ARCI LSD scale (Table 2).
For the 36 mg  dose of dasotraline, small but signiﬁcant differ-
ences compared with placebo were observed in peak effects on
most secondary pharmacodynamic measures (Tables 1 and 2). In
a comparison with both doses of methylphenidate, signiﬁcantly
lower peak effects were observed for the 36 mg dose of dasotra-
line on the following subjective measures of positive drug effect:
Drug Liking VAS, Overall Drug Liking VAS, Take Drug Again VAS, the
ARCI MBG  and Amphetamine scales (but not the BG scale; Table 1);
and SDV, Good Effects VAS, (but not High VAS, Alertness VAS, or
Energized VAS; Table 2).3.3.3. Time course. Fig. 2-A summarizes the time proﬁle over 72 h
post-dose for the Drug Liking VAS for each of the study drugs. As can
be seen, mean scores were higher for the 40 mg  and 80 mg doses
K.S. Koblan et al. / Drug and Alcohol Dependence 159 (2016) 26–34 29
Table  1
Effect of study drugs on pharmacodynamic measures: peak effects at Emax (top panel) and between-drug differences (bottom panel).
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ine at 2–6 h post-dose. The time proﬁle for dasotraline 8 mg  and
6 mg  was similar to that of placebo, while after the ﬁrst 6 h, the
ime proﬁle of dasotraline 36 mg  fell below a VAS score of 50, in
he “disliking” range (Fig. 2-A). For the 36 mg  dose of dasotraline,
verall Drug Liking VAS scores were lower at Emin than placebo
P = 0.004).
.3.4. Subjective drug similarity estimates. Median Drug Similar-
ty VAS scores for placebo, and for the 8 mg  and 16 mg  doses of
asotraline, were all low (<10; not at all similar) when compared
o cocaine and to d-amphetamine/methamphetamine (Fig. 1). In
ontrast, there was a dose-related increase in VAS scores, for
he 40 mg  and 80 mg  doses of methylphenidate, respectively, in
imilarity ratings to cocaine (median values, 34 and 63), and to
-amphetamine/methamphetamine (median values, 48 and 75).
he 36 mg  dose of dasotraline had lower VAS similarity rat-
ngs to d-amphetamine/methamphetamine (median value, 39) and
ocaine (median value, 21) than either dose of methylphenidate
oses (Fig. 1). Median Drug Similarity VAS scores for each study
rug indicated that neither dasotraline (nor methylphenidate)
ere perceived by subjects as having subjective effects similar to
hencyclidine, codeine or morphine, LSD, nicotine, THC, benzodi-
zepines, or ketamine (data not shown).
.3.5. Peak subjective negative effects. There were no signiﬁcant dif-
erences between the 8 mg  and 16 mg  doses of dasotraline and
lacebo in peak negative effects (Bad Effects VAS, Agitation VAS,
RCI LSD scale). For the 36 mg  dose of dasotraline compared to
lacebo, signiﬁcant negative effects were observed on all three
ubjective pharmacodynamic measures (Table 2). A signiﬁcantlygreater peak mean Bad Effects VAS score was  also observed for
the 36 mg  dose of dasotraline compared to methylphenidate 40 mg
(Table 2).
3.4. Pharmacokinetic results
Mean dasotraline plasma concentrations over time following
single-dose oral administration at doses of 8 mg,  16 mg,  and 36 mg
are displayed in Fig. 3. Mean PK parameters after single-dose
administration of dasotraline are summarized in Table 3. As can
be seen, the increase in Cmax and AUC0-last appears to be dose-
proportional across the dosing range examined. The median tmax
ranged from 10 to 12 h across the 3 doses (Table 3).
3.4.1. Pharmacokinetic-Pharmacodynamic correlation. A correla-
tional analysis found no correlation between Drug Liking VAS at
Emax and the Cmax of dasotraline (R2 = 0.01; P = 0.30).
3.4.2. Possible carryover effect. Most of the pre-dose dasotraline
plasma concentrations were below limit of quantiﬁcation (BLQ).
Quantiﬁable pre-dose values (>400 pg/mL), possibly due to carry-
over from the previous dasotraline dose, were reported for a total of
6 subjects who had received the 36 mg  dose of dasotraline as their
previous treatment, and 1 subject who had received the 16 mg dose
of dasotraline as their previous treatment.
3.5. Safety3.5.1. Adverse events. The incidence of adverse events was  simi-
larly low for placebo and the 8 mg  and 16 mg  doses of dasotraline,
except for a higher incidence of insomnia for the 2 dasotraline
30 K.S. Koblan et al. / Drug and Alcohol Dependence 159 (2016) 26–34
Table 2
Effect of study drugs on pharmacodynamic measures: peak effects at Emax (top panel) and between-drug differences (bottom panel).
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mFig. 1. Median drug similarity VAS scores at 24 h post-dose. methylph
oses (approximately 10% for both doses versus 0% for placebo
nd methylphenidate), and headache (23% on the 16 mg  dose
ersus 13% on placebo; Table 4). A higher incidence of adverse
vents was observed on dasotraline 36 mg,  and on the 2 doses
f methylphenidate. The most notable difference was the pres-
nce of insomnia in the dasotraline 36 mg  group compared with
ethylphenidate (31% vs 0%). All adverse events were mild ore 40 mg  80 mg dasotraline 36 mg  16 mg 8 mg placebo .
moderate in severity, with the exception of one severe event that
occurred in a subject taking methylphenidate 40 mg.
One subject (male, age 29) reported suicidal ideation on the
C-SSRS scale at the 5-day follow-up visit after taking 40 mg  of
methylphenidate, but with no method, plan, intent, or behavior.
There were no deaths during the study; three serious adverse
events occurred. One subject (male, age 22) was  diagnosed with
K.S. Koblan et al. / Drug and Alcohol Dependence 159 (2016) 26–34 31
Fig. 2. Time course of mean scores on the following scales: (A) Drug Liking (higher score indicates greater liking); (B) Subjective Drug Value; (C) Any Effects (higher score
indicates greater drug effect); (D) Take Drug Again (higher score indicates more likely to take drug again). methylphenidate 40 mg 80 mg dasotraline 36 mg 16 mg
8 mg placebo .
Fig. 3. Dasotraline plasma concentration over 72 hours post-dose (mean, SD; logarithmic scale) dasotraline 36 mg 16 mg 8 mg.
Table 3
Summary of single dose dasotraline PK parameters.
Dasotraline 8 mg  (N = 42) Dasotraline 16 mg  (N = 43) Dasotraline 36 mg (N = 39)
AUC0-last (h* ng/mL)
Mean (SD) 150 (35) 310 (62) 740 (150)
Median 140 310 730
Geometric mean (%-CV) 140 (23%) 300 (20%) 730 (21%)
Cmax (ng/mL)
Mean (SD) 2.8 (0.6) 5.7 (1.2) 14 (3.4)
Median 2.8 5.8 13
Geometric mean (%-CV) 2.8 (23%) 5.6 (22%) 13 (25%)
tmax (h)
Median 10 10 12
Minimum, Maximum 6.0, 14 6.0, 36 6.1, 24
tmax: time to peak concentration; PK: pharmacokinetic; SD: standard deviation.
AUC 0-last: area under the concentration-time curve from hour zero to last measurable concentration; Cmax: maximum observed plasma concentration; %-CV = percentage
coefﬁcient of variation.
32 K.S. Koblan et al. / Drug and Alcohol Dependence 159 (2016) 26–34
Table 4
Adverse events by treatment at onset (incidence ≥ 10%), n (%).
Placebo (n = 39) Dasotraline 8 mg (n = 42) Dasotraline 16 mg (n = 43) Dasotraline 36 mg (n = 39) MPH  40 mg (n = 40) MPH  80 mg (n = 39)
Any Event 23 (59) 26 (62) 27 (63) 36 (92) 33 (82) 35 (90)
Headache 5 (13) 7 (17) 10 (23) 15 (38) 6 (15) 8 (21)
Euphoric mood 6 (15) 7 (17) 8 (19) 11 (28) 13 (33) 20 (51)
Insomnia 0 (0) 4 (10) 4 (9) 12 (31) 0 (0) 0 (0)
Hypervigilance 4 (10) 2 (5) 4 (9) 8 (21) 12 (30) 8 (21)
Decreased appetite 1 (3) 0 (0) 1 (2) 9 (23) 3 (8) 8 (21)
Palpitations 0 (0) 1 (2) 1 (2) 8 (21) 3 (8) 4 (10)
Dry  mouth 0 (0) 1 (2) 3 (7) 4 (10) 5 (13) 4 (10)
Nausea 1 (3) 0 (0) 1 (2) 6 (15) 4 (10) 2 (5)
Anxiety 0 (0) 1 (2) 1 (2) 5 (13) 1 (2) 4 (10)
Sinus  tachycardia 2 (5) 1 (2) 0 (0) 4 (10) 5 (13) 5 (13)
Sleep  disorder 0 (0) 0 (0) 3 (7) 4 (10) 0 (0) 0 (0)
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euroendocrine carcinoma approximately 43 days after the last
reatment Visit (40 mg  methylphenidate). One subject (male, age
5) was withdrawn from the study due to an episode of vasova-
al syncope during venous catheter insertion at Visit 6. One subject
female, age 31) was withdrawn from the study due to an 11-s run of
ide complex ventricular tachycardia that occurred at 11.5 h after
eceiving dasotraline 36 mg.  The subject was asymptomatic during
he event, and vital signs were within normal limits. No subsequent
bnormalities were found on serial monitoring of ECG parameters
nd cardiac enzymes over the next 36 h.
.5.2. Laboratory. Isolated laboratory abnormalities occurred;
here were no consistent clinically signiﬁcant treatment-related
ffects on any laboratory parameter.
.5.3. Vital signs and ECG. There were small increases in systolic
P, diastolic BP, and heart rate with all study treatments, includ-
ng placebo, from pre-dose to 72 h post-dose. These parameters also
howed a trend increase as the dose of dasotraline increased, begin-
ing at about 4 h post-dose. There were no treatment-emergent
ncreases in QTcF >60 ms,  or QTcF durations >500 ms  (subjects were
xcluded at baseline if a male with QTcF >450 ms,  or female with
TcF >470 ms).
. Discussion
In this randomized, double-blind study involving recreational
timulant users, no differences in peak subjective measures of drug
iking were found for dasotraline (single doses, 8–36 mg)  compared
ith placebo. Peak effects for all 3 doses of dasotraline were not
ifferent from placebo on the primary endpoint (Drug Liking VAS
t Emax), and on the secondary endpoints, Overall Drug Liking VAS
nd High VAS.
The 8 mg  and 16 mg  doses of dasotraline were indistinguishable
rom placebo across all pharmacodynamic measures associated
ith abuse potential. Furthermore, drug similarity VAS scores were
early identical to scores for placebo, indicating that recreational
timulant users perceived the subjective effects of these 2 doses of
asotraline to be “not at all similar” to stimulant drugs.
Differences in peak measures of pharmacodynamic effect
etween dasotraline and placebo became evident at the 36 mg
ose, although the magnitude of differences were small. When
ompared with both doses of methylphenidate, peak effects for
he 36 mg  dose were signiﬁcantly lower across the majority of
ubjective measures of stimulant drug effects, including Drug Lik-
ng VAS, Overall Drug Liking VAS, Good Effects VAS, Take Drug
gain VAS, the ARCI MBG  and Amphetamine scales, and Subjective
rug Value. In addition, the 36 mg  dose of dasotraline was asso-
iated with signiﬁcantly greater negative subjective effects (Bad2 (5) 3 (8) 5 (13)
Effects VAS, Agitation VAS, ARCI LSD scale) in comparison to both
methylphenidate and placebo, suggesting that subjects perceived
this dose as having aversive properties.
The validity of the current study as an assay of abuse potential
was conﬁrmed by the signiﬁcant effects observed for both doses of
methylphenidate compared to placebo on the primary measure,
Drug Liking VAS, and on secondary measures indicating strong
stimulant effects. These ﬁndings were consistent with results
for methylphenidate reported in previous studies (Heishman and
Henningﬁeld, 1991; Stoops et al., 2005; Jasinski, 2000; Kollins et al.,
2001; Clemow and Walker, 2014).
It should be noted that a comparison of immediate-release
methylphenidate and extended-release formulations, such as
osmotic-release oral system (OROS) methylphenidate, has found
signiﬁcant drug liking and abuse potential for extended-release
drugs compared with placebo in subjects with a history of recre-
ational stimulant use (Parasrampuria et al., 2007a,b). However,
drug liking and positive effects were lower (occasionally at a
signiﬁcant level) for the extended-release methylphenidate for-
mulation compared with the IR formulation, especially in the
ﬁrst 1–2 h post-dose. Comparable ﬁndings have been reported in
healthy volunteers (Kollins et al., 1998). Interestingly, a poor cor-
relation has been reported between the plasma concentration of
methylphenidate at a given time-point, and subjective pharma-
codynamic measures (Parasrampuria et al., 2007a,b). Data such
as these have led to the hypothesis that subjective response to
methylphenidate (and other drugs of abuse) is largely determined,
not by the absolute drug concentration, but by the rate of increase
in plasma concentration and DAT occupancy (Volkow et al., 1995;
Volkow and Swanson, 2003; Swanson and Volkow, 2003; Kollins
et al., 1998; Spencer et al., 2012). The delayed tmax (10–12 h) of
dasotraline, and the more gradual rate of increase in plasma and
CNS concentrations of drug, may  contribute to the low drug liking
and low abuse potential observed in the current study.
Drugs with short elimination half-lives have also been shown
to have increased risk of abuse liability (reviewed by Busto and
Sellers, 1986; Farré and Camí, 1991). In short half-life drugs, rapid
reduction in plasma concentrations is associated with withdrawal
effects that result in increased rates of drug administration (Quinn
et al., 1997). In comparison to the short (2–3 h) elimination half-
life of methylphenidate, the long (47–77 h) half-life of dasotraline
avoids this PK-related rapid onset/offset effect.
Comparable low abuse potential has also been reported for
the novel triple (DAT, NET, SERT) reuptake inhibitor, tesofensine,
which also has a delayed tmax of approximately 6 h, and a very
long half-life (∼200 h; Schoedel et al., 2010). In a placebo- and
active-comparator controlled crossover study in recreational
stimulant users, the abuse potential of tesofensine was found to be
similar to placebo, and to the NET reuptake inhibitor, atomoxetine,
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nd signiﬁcantly lower than the 30 mg  dose of d-amphetamine
Schoedel et al., 2010). Dasotraline appears to have a low abuse
otential based on the results of this study that is similar to the
on-CNS stimulant medications used in ADHD such as atomoxe-
ine (Heil et al., 2002; Jasinski et al., 2008), and signiﬁcantly less
han what has been consistently reported for both short-acting
Kollins et al., 2001; Heil et al., 2002) and long-acting formulations
f CNS stimulants (Parasrampuria et al., 2007a,b; Kollins et al.,
001; Spencer et al., 2012).
Meta-analyses of short-term studies of adult ADHD indicate that
reatment with the NET inhibitor atomoxetine is associated with
otably smaller effect sizes compared to effects sizes observed for
timulant medications (Faraone and Glatt, 2010). The results of the
urrent study suggest that there is a potential therapeutic role for
edications with a pharmacologic proﬁle that combine both DAT
nd NET inhibition, but without the abuse liability associated with
rugs that increase dopamine levels.
The 8 mg  and 16 mg  doses of dasotraline were generally well-
olerated in this study, with an incidence of adverse events that was
imilar to placebo, with the exception of higher rates of headache
NNH = 10 vs placebo) on the 16 mg  dose, and insomnia (NNH = 10
s placebo) on the 8 mg  and 16 mg  doses. There was  a notable
ose-related increase in adverse events at the 36 mg  dose of daso-
raline, however, no adverse events were rated as “severe” at this
ose.
There were small dose-related increases in blood pressure and
eart rate, and isolated reports of adverse events related to vital
igns, ECG, and laboratory tests, but there were no consistent
asotraline-related effects of any clinical signiﬁcance on these
arameters.
.1. Limitations
Potential limitations of the current study concern the design
f the study, and the patient population enrolled. A key concern
as providing sufﬁcient washout period for a drug, dasotraline,
ith an elimination half-life of 47–77 h. A minimum of 21 days
as required between doses in the treatment phase. Nonetheless, 7
ubjects had pre-dose dasotraline plasma concentrations that were
bove the lower limit of quantiﬁcation (<400 pg/mL). Because of the
1 day washout period, the duration of the study was  considerably
onger than most human abuse potential studies. As a result, the
ttrition rate was higher than is commonly reported. The potential
ias this may  have introduced into the population studied is uncer-
ain. Finally, it is important to note that several of the subjective
harmacodynamic measures were administered as unipolar scales.
lthough all the scales administered in the current study are consis-
ent with the FDA Draft guidance (Food and Drug Administration,
010, 2013) and those used in previous studies of human abuse
otential, use of unipolar scales may  be associated with a greater
xpectancy bias, especially for drugs that have only modest effects
Shram et al., 2012).
.2. Conclusions
This double-blind study, in a recreational stimulant user popula-
ion, found that single doses of dasotraline, ranging from 8 to 36 mg,
ere not associated with statistically or clinically signiﬁcant dif-
erences from placebo on either the primary endpoint, Drug Liking
t Emax, or on the global secondary endpoint, Overall Drug Liking.
he ﬁndings of low abuse potential for dasotraline in this study
re consistent with its PK proﬁle, which is characterized by slow
bsorption and gradual elimination. Ultimately long-term stud-
es with repeated dosing will provide conﬁrmation of the abuse
iability proﬁle of dasotraline.ependence 159 (2016) 26–34 33
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